Similarly, using the ≥150 nmol/L threshold employed in clinical trials of Lp(a)-lowering therapies (eg, OCEAN(a)-DOSE and Lp(a)HORIZON), individuals above this level had 93% increased odds of AAA (OR: 1.93; 95% CI: 1.65-2.28; P < 0.01). This evidence concerns the gene LPA and triple-A syndrome.